HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

IAXO-102

a Toll-like receptor-4 antagonist; structure in first source

Networked: 6 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycoconjugates: 1353
  - Glycolipids: 2799
    - IAXO-102: 6
- Amino Sugars: 110
  - IAXO-102: 6
Lipids: 114793
- Glycolipids: 2799
  - IAXO-102: 6

Experts

1.	Kawakita, Fumihiro: 1 article (02/2019)
2.	Liu, Lei: 1 article (02/2019)
3.	Nakano, Fumi: 1 article (02/2019)
4.	Nishikawa, Hirofumi: 1 article (02/2019)
5.	Okada, Takeshi: 1 article (02/2019)
6.	Suzuki, Hidenori: 1 article (02/2019)
7.	Cockerill, Gillian: 1 article (10/2015)
8.	Huggins, Christopher: 1 article (10/2015)
9.	Neumann, Frank: 1 article (10/2015)
10.	Pearce, Stuart: 1 article (10/2015)

Related Diseases

1.	Brain Edema (Cerebral Edema) 02/01/2019 - "IAXO-102 significantly prevented post-SAH neurological impairments, brain edema, and BBB disruption, resulting in improved survival rates. "
2.	Inflammation (Inflammations) 01/01/2022 - "We, therefore, aimed to investigate the potential of the TLR4 antagonist, IAXO-102, to attenuate gastrointestinal inflammation as well as supress tumour activity in a colorectal-tumour-bearing mouse model of GIM induced by CPT-11. " 01/01/2023 - "The in silico rational presented here supports further investigation of the binding activity of IAXO-102 and TAK-242 for their potential application in the prevention of gastrointestinal inflammation caused by SN-38." 01/01/2023 - "This structural study aimed to provide in silico rational of the recognition and potential binding of TLR4 ligands IAXO-102, TAK-242, and SN-38 (the toxic metabolite of the chemotherapeutic irinotecan hydrochloride), which could contribute to rationale development of therapeutic anti-inflammation drugs targeting TLR4 in the gastrointestinal tract. "
3.	Abdominal Aortic Aneurysm 10/01/2015 - "The main goal of this study was to determine the potential of IAXO-102 (Innaxon, Tewkesbury), a novel small molecule TLR4 antagonist, to modulate non-hematopoietic TLR4 proinflammatory signalling and inhibit experimental abdominal aortic aneurysm (AAA) development. "
4.	Mucositis 02/01/2023 - "TLR4 antagonism using specific inhibitors TAK-242 and IAXO-102 was not effective at blocking IM in these pre-clinical models of mucositis. "
5.	Reperfusion Injury 04/01/2023 - "Protective effect of IAXO-102 on renal ischemia-reperfusion injury in rats."

Related Drugs and Biologics

1.	Irinotecan (Camptosar)
2.	ethyl 6- (N- (2- chloro- 4- fluorophenyl)sulfamoyl)cyclohex- 1- ene- 1- carboxylate
3.	Ligands
4.	Tight Junction Proteins
5.	JNK Mitogen-Activated Protein Kinases
6.	Matrix Metalloproteinase 9 (Gelatinase B)
7.	Protein Isoforms (Isoforms)
8.	Lipopolysaccharides
9.	Angiotensin II
10.	Periostin